Payment overview · 2025
General Payments
$468.56
22 reported records · 14 companies
Healthcare provider profile · identity verified
Sandra Rocha, DO
Allopathic & Osteopathic Physicians|Family Medicine · EL PASO, TX · NPI 1518938687
Verified facts
What the public records show
CMS Open Payments records show Sandra Rocha, DO received $468.56 in general payments during 2025 across 22 reported records.
Abbott Laboratories accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.38 | 20.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.68 | 15.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.72 | 14.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.19 | 10.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.98 | 6.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.55 | 5.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.70 | 4.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.99 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.79 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.27 | 3.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.21 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.58 | 3.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.49 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.03 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $468.56 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $94.38 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.72 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.72 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 113 |
| Metformin Hcl | Metformin Hcl | 260 | 79 |
| Losartan Potassium | Losartan Potassium | 215 | 63 |
| Gabapentin | Gabapentin | 191 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 49 |
| Omeprazole | Omeprazole | 182 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 56 |
| Lisinopril | Lisinopril | 129 | 43 |
| Famotidine | Famotidine | 123 | 46 |
| Allopurinol | Allopurinol | 120 | 35 |
| Tramadol Hcl | Tramadol Hcl | 117 | 30 |
| Montelukast Sodium | Montelukast Sodium | 112 | 40 |
| Farxiga | Dapagliflozin Propanediol | 110 | 30 |
| Carvedilol | Carvedilol | 97 | 25 |
| Trazodone Hcl | Trazodone Hcl | 94 | 26 |
| Bupropion Xl | Bupropion Hcl | 92 | 29 |
| Glipizide | Glipizide | 92 | 26 |
| Ozempic | Semaglutide | 92 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 27 |
| Alprazolam | Alprazolam | 86 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 24 |
| Potassium Chloride | Potassium Chloride | 79 | 28 |
| Ibandronate Sodium | Ibandronate Sodium | 77 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 32 |
| Ezetimibe | Ezetimibe | 71 | 32 |
| Sertraline Hcl | Sertraline Hcl | 71 | 28 |
| Furosemide | Furosemide | 69 | 30 |
| Mounjaro | Tirzepatide | 69 | 12 |
| Eliquis | Apixaban | 66 | 16 |
| Alendronate Sodium | Alendronate Sodium | 65 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 24 |
| Meloxicam | Meloxicam | 65 | 26 |
| Simvastatin | Simvastatin | 62 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 11 |
| Synthroid | Levothyroxine Sodium | 58 | 18 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 18 |
| Pregabalin | Pregabalin | 52 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 15 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 17 |
| Glipizide Er | Glipizide | 42 | 12 |
| Spironolactone | Spironolactone | 42 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 41 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 40 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 38 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 17 |
| Estradiol | Estradiol | 34 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Baclofen | Baclofen | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Naproxen | Naproxen | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Clotrimazole | Clotrimazole | 16 | 13 |
| Linzess | Linaclotide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $468.56 · 22 records | Abbott Laboratories | ACCRUFER, AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, IBSRELA, INSPIRE, LINZESS, MOUNJARO, OTEZLA, Ozempic, REPATHA, SHINGRIX, Symbravo, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error